This study is for kids aged 2 to under 18 years who have specific types of tumors that show a protein called somatostatin receptor (SSTR). The study will check how safe and effective a medicine called Lutetium Lu 177 Edotreotide is. This medicine is a type of Targeted Radiopharmaceutical Therapy (RPT), which means it uses special radioactive materials to target and treat cancer cells. The medicine will be given through an IV every 8 weeks, up to 6 times over about 48 weeks.

• The study requires regular visits every 8 weeks for up to 6 doses.
• Participants must have a specific type of tumor that shows SSTR and has not responded to previous treatments.
• Certain health conditions and past treatments could disqualify participants.

Children who join should have a confirmed SSTR-positive tumor and must not have certain health issues, like severe kidney or liver problems. Parents or guardians need to sign a consent form before participation, and if suitable, kids will also give their agreement, called assent.